Cargando…

In vivo studies on antibiotic combination for the treatment of carbapenem-resistant Gram-negative bacteria: a systematic review and meta-analysis protocol

OBJECTIVE: There is poor evidence to determine the superiority of combination regimens versus monotherapy against infections due to carbapenem-resistant (CR) Gram-negative bacteria. In vivo models can simulate the pathophysiology of infections in humans and assess antibiotic efficacy. We aim to inve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Righi, Elda, Scudeller, Luigia, Chiamenti, Margherita, Abdelraouf, Kamilia, Lodise, Thomas, Carrara, Elena, Savoldi, Alessia, Menghin, Dario, Pellizzari, Gloria, Ellis, Sally, Franceschi, Francois, Piddock, Laura, Rebuffi, Chiara, Sanguinetti, Maurizio, Tacconelli, Evelina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647577/ https://www.ncbi.nlm.nih.gov/pubmed/35047691 http://dx.doi.org/10.1136/bmjos-2019-100055

Ejemplares similares

The role of combination therapy in the treatment of severe infections caused by carbapenem resistant gram-negatives: a systematic review of clinical studies
por: Savoldi, Alessia, et al.
Publicado: (2021)

Colonisation with Extended-Spectrum Cephalosporin-Resistant Enterobacterales and Infection Risk in Surgical Patients: A Systematic Review and Meta-analysis
por: Righi, Elda, et al.
Publicado: (2023)

1544. Efficacy of Human-Simulated Cefiderocol Exposure Against Gram-Negative Bacteria in an Iron-Overloaded Murine Thigh Infection Model
por: Kidd, James M, et al.
Publicado: (2019)

Personalized infection prevention and control: a concept whose time has arrived
por: Savoldi, Alessia, et al.
Publicado: (2023)

1336. Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) Against Carbapenems-Resistant Acinetobacter baumannii (CR-ACBN) in the Neutropenic Murine Thigh Infection Model
por: Abuhussain, Safa Almarzoky, et al.
Publicado: (2018)

1405. Efficacy of the Human-Simulated Regimen (HSR) of Cefepime (FEP)/VNRX-5133 Combination Against Serine β-Lactamase-Producing Gram-negative Bacteria in the Neutropenic Murine Thigh Infection Model
por: Abdelraouf, Kamilia, et al.
Publicado: (2018)

1245. In Vivo Efficacy of WCK 4282 (High Dose Cefepime [FEP]-Tazobactam [TZB]) Against β-Lactamase-Producing (BLP) Gram-Negative Bacteria in a Neutropenic Murine Pneumonia Model
por: Lasko, Maxwell J, et al.
Publicado: (2020)

O046: Impact of infections due to carbapenem resistant gram negatives on length of hospitalisation: multi state model approach
por: De Angelis, G, et al.
Publicado: (2013)

1191. Prevalence and Microbiology of Carbapenem Resistance Among Six Gram-Negative Pathogens in Bloodstream Infections in US Hospitals, 2010–2015
por: Lodise, Thomas P, et al.
Publicado: (2018)

Pitfalls of Computed Tomography in the Coronavirus 2019 (COVID-19) Era: A New Perspective on Ground-Glass Opacities
por: Mehrabi, Sara, et al.
Publicado: (2020)

A Review of Vaccinations in Adult Patients with Secondary Immunodeficiency
por: Righi, Elda, et al.
Publicado: (2021)

A 2020 review on the role of procalcitonin in different clinical settings: an update conducted with the tools of the Evidence Based Laboratory Medicine
por: Azzini, Anna Maria, et al.
Publicado: (2020)

Impact of COVID-19 and Antibiotic Treatments on Gut Microbiome: A Role for Enterococcus spp.
por: Righi, Elda, et al.
Publicado: (2022)

Assessment of COVID-19 progression on day 5 from symptoms onset
por: Gentilotti, Elisa, et al.
Publicado: (2021)

Comparison of Risk Factors and Outcomes in Carbapenem-Resistant and Carbapenem-Susceptible Gram-Negative Bacteremia
por: Cetin, Sinan, et al.
Publicado: (2021)

Effectiveness of a double-carbapenem combinations against carbapenem-resistant Gram-negative bacteria
por: Lu, Jiayue, et al.
Publicado: (2022)

164. Analysis of Adult, Hospitalized Patients With Carbapenem-resistant (CR) Gram-Negative Bloodstream Infections (GN-BSIs) due to Lactose Fermenters (LFs) and Non-lactose Fermenters (NLFs): Is There a Difference in Outcomes?
por: Lodise, Thomas, et al.
Publicado: (2019)

Imipenem/funobactam (formerly XNW4107) in vivo pharmacodynamics against serine carbapenemase-producing Gram-negative bacteria: a novel modelling approach for time-dependent killing
por: Fratoni, Andrew J, et al.
Publicado: (2023)

Impact of implementing a non-restrictive antibiotic stewardship program in an emergency department: a four-year quasi-experimental prospective study
por: Savoldi, Alessia, et al.
Publicado: (2020)

Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria
por: Nordmann, Patrice, et al.
Publicado: (2019)

Global Threat of Carbapenem-Resistant Gram-Negative Bacteria
por: Jean, Shio-Shin, et al.
Publicado: (2022)

1312. Metallo-β-lactamase-Producing Enterobacterales (MBL-EB): Is it Time to Rethink Our Assessment Tools?
por: Abdelraouf, Kamilia, et al.
Publicado: (2020)

In vivo pharmacokinetic/pharmacodynamic evaluation of cefepime/taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model
por: Abdelraouf, Kamilia, et al.
Publicado: (2023)

Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments
por: Gupta, Akshita, et al.
Publicado: (2023)

Antimicrobial resistance rates in gram-positive bacteria do not drive glycopeptides use
por: Gladstone, Beryl Primrose, et al.
Publicado: (2017)

The role of carbapenems in initial therapy for serious Gram-negative infections
por: Rahal, James J
Publicado: (2008)

Optimizing the use of carbapenems in the face of increasing Gram-negative resistance
por: Ramphal, Reuben
Publicado: (2008)

Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens
por: Lee, Chang-Seop, et al.
Publicado: (2014)

Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections
por: Doi, Yohei
Publicado: (2019)

Editorial: The global threat of carbapenem-resistant gram-negative bacteria
por: Dropa, Milena, et al.
Publicado: (2022)

1299. In Vitro-In Vivo Discordance with β-lactams against Metallo-β-lactamase-Producing Enterobacterales: Implications for Susceptibility Testing
por: Abdelraouf, Kamilia, et al.
Publicado: (2020)

Evaluating the Efficacies of Carbapenem/β-Lactamase Inhibitors Against Carbapenem-Resistant Gram-Negative Bacteria in vitro and in vivo
por: El Hafi, Bassam, et al.
Publicado: (2019)

Safety of a Carbapenem Restriction Policy in Patients with Gram-Negative Bacteremia
por: Mani, Nandita S, et al.
Publicado: (2017)

Risk Factors for Development of Carbapenem Resistance Among Gram-Negative Rods
por: Richter, Stefan E, et al.
Publicado: (2019)

Molecular epidemiology & therapeutic options of carbapenem-resistant Gram-negative bacteria
por: Garg, Atul, et al.
Publicado: (2019)

Attributable burden in patients with carbapenem-nonsusceptible gram-negative respiratory infections
por: Tabak, Ying P., et al.
Publicado: (2020)

The Place of Meropenem–Vaborbactam in the Management of Carbapenem-Resistant Gram-Negative Infections
por: Chopra, Teena
Publicado: (2021)

Emergence of Carbapenem-Resistant Gram-Negative Isolates in Hospital Settings in Djibouti
por: Ragueh, Ayan Ali, et al.
Publicado: (2023)

663. Incidence of Acute Kidney Injury (AKI) among Adult Hospitalized Patients (pts) with Carbapenem Resistant Gram-Negative Infections (CR-GNIs) Who Received Early Targeted Treatment (TX) with a Newer β-Lactam (BL)-, Colistin (COL)-, or Aminoglycoside (AG)-Containing Regimen
por: Lodise, Thomas, et al.
Publicado: (2022)

1397. Comparative Efficacy of Human-Simulated Epithelial Lining Fluid (ELF) Exposures of Tedizolid (TZD) Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Neutropenic (I−) vs. Immunocompetent (I+) Murine Models of Pneumonia
por: Kidd, James M, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_g6m47quoh860d56j9mabaius0b